Sanofi said it plans to separate its consumer health division, probably through a spinoff, as the French drugmaker deepens its focus on cutting-edge medicines and vaccines.

Sanofi is reviewing options for the potential split, but said the most likely course would be a “capital markets transaction” to form a separately listed company based in France. The move could occur as soon as the fourth quarter of 2024, it said in a statement Friday.